Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).

about

Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).

Item

http://www.wikidata.org/entity/Q47869675

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Using the Modified Magee Equat ...... ore Assay (Oncotype DX Assay).

@en

Using the Modified Magee Equat ...... 21-Gene Recurrence Score Assay

@nl

type

Item

label

Using the Modified Magee Equat ...... ore Assay (Oncotype DX Assay).

@en

Using the Modified Magee Equat ...... 21-Gene Recurrence Score Assay

@nl

prefLabel

Using the Modified Magee Equat ...... ore Assay (Oncotype DX Assay).

@en

Using the Modified Magee Equat ...... 21-Gene Recurrence Score Assay

@nl

P1476

Using the Modified Magee Equat ...... ore Assay (Oncotype DX Assay).

@en

P2093

Debra L Zynger

http://www.w3.org/2001/XMLSchema#string

Gary Tozbikian

http://www.w3.org/2001/XMLSchema#string

Yanjun Hou

http://www.w3.org/2001/XMLSchema#string

Zaibo Li

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

P304

541-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/AJCP/AQX008

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28449064

http://www.w3.org/2001/XMLSchema#string